NewsRelease
ResearchArticle Cites Cleanascite™ for Proteome Analysis of Human BileAssociated with Primary Sclerosing Cholangitis Disease
MONMOUTHJUNCTION, NJ, November22, 2019 -- Biotech Support Group reports on a recent researcharticle describing the simplicity and efficiency of their lipidclearance sample preparation technology for the proteomic analysis ofbile fluid.
Vesterhus,Mette, et al. "Novelserum and bile protein markers predict primary sclerosing cholangitisdisease severity and prognosis." Journal of hepatology 66.6(2017): 1214-1222.
Theinvestigators aimed to identify novel protein biomarkers of diseaseseverity and prognosis in primary sclerosing cholangitis (PSC), usinga bead-based array targeting 63 proteins.The article states for Bile sample preparation, “The samples werethawed and 100 µL of bile was added to 150 µL PBS containing 0.1%Tween 20 and Protease Inhibitor Cocktail (Sigma-Aldrich, St. Louis,Missouri, USA), then centrifuged at 4 °C for 10 minutes at 14000rpm. Cleanascite™ (100 µL, Biotech Support Group, NJ, USA) andProtein G Sepharose (50 µL; Sigma-Aldrich) were used for removal oflipids and immunoglobulins, respectively.” Theauthors conclude with the identification of novelbiliary and serum biomarkers of severity and prognosis in PSC.
“Thisreference shows the versatility of Cleanascite™ to efficientlyremove lipids from bile fluid, with a selectivity profile suitablefor proteome analysis using bead-based capture features.” statesSwapan Roy, Ph.D., President and Founder of Biotech Support Group.
Formore information visit: Cleanascite™ Lipid Removal Reagent andClarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866